New antibody drug shows promise in early cancer trial

NCT ID NCT06929195

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a safe dose and check for early signs of tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

    Changsha, Hunan, 410005, China

  • Shanghai Tenth Hospital, Tongji University

    Shanghai, Shanghai Municipality, 200032, China

  • The Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000, China